NRXP Research and Charts

NRXP - NRX Pharmaceuticals Inc Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-19 (Delayed quote data 2025-01-03)

Last 2.69	Change ⇓ -0.30 (-10.03%)	Volume 5,016,834
	Open 3.13	High 3.74	Low 2.60

8EMA (Daily) 2.11	40EMA (Daily) 1.55	50EMA (Daily) 1.54	STO (Daily) 61.337	MACD Hist (Daily) 0.310
8EMA (Weekly) 1.669	40EMA (Weekly) 1.69	50EMA (Weekly) 1.67	STO (Weekly) 38.143	MACD Hist (Weekly) 0.211


Company Profile
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.